Utah 2024 Regular Session

Utah Senate Bill SB0071

Introduced
1/16/24  
Refer
1/17/24  
Report Pass
2/21/24  
Engrossed
2/26/24  
Refer
2/26/24  
Report Pass
2/27/24  

Caption

Cannabis Business Tax Credit Amendments

Impact

If enacted, SB 71 would amend existing Utah tax code to lower operational costs for licensed medical cannabis businesses, thereby potentially encouraging more entities to enter this market. Additionally, by setting a clear tax credit structure, the bill aims to simplify the financial planning for cannabis businesses and clarify the benefits they may receive. This adjustment in the legal framework underlines the state's commitment to fostering economic growth within the cannabis industry while ensuring tax compliance and oversight.

Summary

Senate Bill 71, also known as the Cannabis Business Tax Credit Amendments, introduces a nonrefundable income tax credit aimed at alleviating financial burdens on businesses involved in selling medical cannabis within the state of Utah. The bill is designed to support those entities by allowing them to claim a tax credit equal to 1.8% of their qualifying tax liability related to medical cannabis activities. This legislative move reflects an ongoing effort to stabilize and promote the medical cannabis market in Utah, responding to the growing demand for these services since the legalization of medical cannabis in the state.

Sentiment

General sentiment around the bill appears to lean positively among stakeholders within the cannabis industry, reflecting a recognition of the financial challenges faced by cannabis businesses in the early stages of operation. Proponents argue that this tax credit will promote a more competitive environment conducive to growth and compliance. However, there remains cautious optimism, as some legislators and community members express concerns about the potential for increasing cannabis availability and affecting public health initiatives.

Contention

Notable points of contention include the balance between supporting business development while maintaining regulatory oversight surrounding medical cannabis sales. Critics argue that tying tax benefits to cannabis operations may encourage wider availability, raising concerns about health and safety implications. Furthermore, the bill's retrospective provisions, which provide the potential for credits to beneficiaries from the start of the 2024 tax year, have raised questions regarding the implications for state tax revenues and the fairness of such measures.

Companion Bills

No companion bills found.

Previously Filed As

UT SB0137

Medical Cannabis Amendments

UT SB0278

Cannabis Business Tax Credit Amendments

UT SB0091

Medical Cannabis Regulation Amendments

UT HB0072

Medical Cannabis Governance Revisions

UT SB0036

Professional Licensing Amendments

UT SB0082

Sales Tax Amendments

UT SB0171

Health Care Practitioner Liability Amendments

UT SB0272

Funds Amendments

UT SB0016

Transgender Medical Treatments and Procedures Amendments

UT HB0230

Center for Medical Cannabis Research

Similar Bills

CA AB913

Pharmacy benefit managers.

CA SB362

Chain community pharmacies: quotas.

LA HB432

Provides for the regulation of pharmacy services administrative organizations (OR +$88,000 SG EX See Note)

MS HB1125

Pharmacy services; prohibit insurers and PBMs from requiring persons to obtain exclusively through pharmacies that they own.

CA AB401

Pharmacy: remote dispensing site pharmacy: telepharmacy: shared clinic office space.

LA HB387

Provides for the regulation of pharmacy services administrative organizations

MS HB1119

Pharmacy benefit managers; revise provisions related to.

CA AB690

Pharmacies: relocation: remote dispensing site pharmacy: pharmacy technician: qualifications.